- Home
- ALXO vs ARMP Comparison
ALXO vs ARMP Comparison
Compare ALXO & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- ARMP
- Stock Information
- Founded
- ALXO 2015
- ARMP N/A
- Country
- ALXO United States
- ARMP United States
- Employees
- ALXO N/A
- ARMP N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALXO Health Care
- ARMP Health Care
- Exchange
- ALXO Nasdaq
- ARMP Nasdaq
- Market Cap
- ALXO 76.5M
- ARMP 80.0M
- IPO Year
- ALXO 2020
- ARMP N/A
- Fundamental
- Price
- ALXO $1.74
- ARMP $2.06
- Analyst Decision
- ALXO Buy
- ARMP Strong Buy
- Analyst Count
- ALXO 6
- ARMP 1
- Target Price
- ALXO $11.00
- ARMP $7.00
- AVG Volume (30 Days)
- ALXO 1.1M
- ARMP 13.8K
- Earning Date
- ALXO 03-06-2025
- ARMP 11-13-2024
- Dividend Yield
- ALXO N/A
- ARMP N/A
- EPS Growth
- ALXO N/A
- ARMP N/A
- EPS
- ALXO N/A
- ARMP N/A
- Revenue
- ALXO N/A
- ARMP $5,467,000.00
- Revenue This Year
- ALXO N/A
- ARMP $23.87
- Revenue Next Year
- ALXO N/A
- ARMP N/A
- P/E Ratio
- ALXO N/A
- ARMP N/A
- Revenue Growth
- ALXO N/A
- ARMP 34.92
- 52 Week Low
- ALXO $1.19
- ARMP $1.80
- 52 Week High
- ALXO $17.83
- ARMP $4.48
- Technical
- Relative Strength Index (RSI)
- ALXO 53.13
- ARMP 49.88
- Support Level
- ALXO $1.56
- ARMP $1.97
- Resistance Level
- ALXO $1.94
- ARMP $2.28
- Average True Range (ATR)
- ALXO 0.16
- ARMP 0.14
- MACD
- ALXO -0.01
- ARMP 0.01
- Stochastic Oscillator
- ALXO 50.00
- ARMP 54.17
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.